Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
주식 순위 #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
주가
$3.09
시가총액
$58.82M
변동 (1일)
0.33%
변동 (1년)
-73.01%
국가
US
거래 Elicio Therapeutics, Inc. (ELTX)

카테고리

Elicio Therapeutics, Inc. (ELTX)의 주가 이력
최고 종가: $3.10 (2026-08-01 기준)

최저 종가: $5.88 (2023-11-01 기준)
Elicio Therapeutics, Inc.의 주가 이력 (2023 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 9.17%
2025 59.27%
2024 -21.55%
2023 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$549.84 38.34%
US
$1.05K 58.20%
NL
$150.50 473.99%
US
$118.70 -18.24%
AU
$770.19 9.84%
CH